文献速递浆细胞疾病淋巴瘤

免疫调节药物抑制树突状细胞的Th1诱导能力但增强Th2介导的过敏反应

Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.
PubMed 文献 · Blood Adv · 2020-01-01

本研究分析来那度胺和泊马度胺对人类髓系树突状细胞(mDCs)的影响及其在过敏中的作用。临床浓度下两种药物不影响mDCs存活及CD86和OX40配体表达,但剂量依赖性抑制LPS诱导的IL-12和TNF产生及STAT4表达,增强IL-10产生;TSLP刺激下显著增强CCL17产生及STAT6和IRF4表达,促进记忆Th2细胞反应。46例骨髓瘤患者中,来那度胺相关皮疹发生时血清CCL17水平显著高于无皮疹者及治疗前,达VGPR者血清CCL17水平显著高于未达VGPR者,有皮疹者至下次治疗中位时间显著更长。

要点

  • 来那度胺和泊马度胺抑制mDCs的Th1诱导能力,促进Th2反应。
  • 来那度胺相关皮疹发生时血清CCL17水平显著升高。
  • 有皮疹的来那度胺治疗患者至下次治疗中位时间显著更长。

核心结论

  • 免疫调节药物抑制树突状细胞的Th1诱导能力,转而促进Th2反应,来那度胺相关皮疹可能是Th2轴激活驱动的过敏反应,临床疗效与皮疹通过免疫刺激密不可分。

研究设计与样本

  • 体外分析免疫调节药物对人髓系树突状细胞的影响,并在46例骨髓瘤患者中分析血清CCL17水平与来那度胺相关皮疹及疗效的关系。

主要发现

  • 临床浓度的来那度胺和泊马度胺不影响LPS和TSLP刺激下血液mDCs的存活及CD86和OX40配体表达。
  • 来那度胺和泊马度胺剂量依赖性抑制LPS诱导的IL-12和TNF产生及STAT4表达,并增强IL-10产生。
  • TSLP刺激下两种药物显著增强CCL17产生及STAT6和IRF4表达,促进记忆Th2细胞反应。
  • 46例骨髓瘤患者中,来那度胺相关皮疹发生时血清CCL17水平显著高于治疗期间无皮疹者及治疗前。
  • 来那度胺治疗期间达VGPR者血清CCL17水平显著高于未达VGPR者,有皮疹者至下次治疗中位时间显著长于无皮疹者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide, are widely used treatments for multiple myeloma; however, they occasionally lead to episodes of itchy skin and rashes. Here, we analyzed the effects of IMiDs on human myeloid dendritic cells (mDCs) as major regulators of Th1 or Th2 responses and the role they play in allergy. We found that lenalidomide and pomalidomide used at clinical concentrations did not affect the survival or CD86 and OX40-ligand expression of blood mDCs in response to lipopolysaccharide (LPS) and thymic stromal lymphopoietin (TSLP) stimulation. Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS. When stimulated with TSLP, both IMiDs significantly enhanced CCL17 production and STAT6 and IRF4 expression and promoted memory Th2-cell responses. In 46 myeloma patients, serum CCL17 levels at the onset of lenalidomide-associated rash were significantly higher than those without rashes during lenalidomide treatment and those before treatment. Furthermore, serum CCL17 levels in patients who achieved a very good partial response (VGPR) were significantly higher compared with a less than VGPR during lenalidomide treatment. The median time to next treatment was significantly longer in lenalidomide-treated patients with rashes than those without. Collectively, IMiDs suppressed the Th1-inducing capacity of DCs, instead promoting a Th2 response. Thus, the lenalidomide-associated rashes might be a result of an allergic response driven by Th2-axis activation. Our findings suggest clinical efficacy and rashes as a side effect of IMiDs are inextricably linked through immunostimulation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Phan V, Ito T, Inaba M, et al. Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. Blood Adv. 2020. PMID: 32761232. doi:10.1182/bloodadvances.2019001410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。